Leber Congenital Amaurosis Market Growth Potential: What The Latest Forecast Reveals

Leber Congenital Amaurosis Market Report

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Leber Congenital Amaurosis Market Forecast: What Value Will The Market Reach By 2030?

The market size for leber congenital amaurosis has shown significant expansion in recent years. This market is anticipated to expand from $1.06 billion in 2025 to $1.12 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.5%. The growth observed in the past can be attributed to several factors, including the scarcity of treatment options for inherited retinal disorders, a heightened understanding of rare genetic eye diseases, innovations in retinal imaging technologies, an increase in pediatric ophthalmology services, and initial breakthroughs in gene replacement therapy research.

The leber congenital amaurosis market size is projected to experience robust growth in the coming years. It is forecast to expand to $1.39 billion by 2030, achieving a compound annual growth rate (CAGR) of 5.5%. This growth throughout the forecast period stems from factors such as increasing investment in ophthalmic gene therapy research, the expansion of precision medicine initiatives, a rising number of regulatory approvals for rare disease treatments, wider adoption of advanced genetic testing, and enhanced healthcare access for rare genetic disorders. Prominent trends anticipated in the forecast period include a broader scope of gene therapy approvals for inherited retinal diseases, a heightened focus on early genetic screening and diagnosis, an increase in clinical trials for novel retinal regeneration therapies, growing use of assistive vision technologies, and advancements in retinal prosthesis and bionic eye solutions.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=10831131&type=smp&name=Leber%20Congenital%20Amaurosis%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Leber Congenital Amaurosis Market Growth Backed By Core Demand Fundamentals

The expansion of the leber congenital amaurosis (LCA) market is anticipated, driven by the rising occurrence of inherited retinal diseases. These conditions, known as Inherited Retinal Diseases (IRDs), are genetic ailments that impact the retina, the ocular tissue critical for sight. The surge in inherited retinal diseases is linked to advancements in genetic testing, heightened awareness, better diagnostic methods, and increased longevity. Enhanced genetic testing capabilities have simplified the detection of inherited retinal diseases, resulting in a greater number of identified instances. Leber congenital amaurosis plays a role in deepening our comprehension of inherited retinal diseases by uncovering genetic mutations and underlying disease processes, which in turn aids in creating specific therapies and interventions. As an illustration, data from January 2025, provided by the UK Parliament’s House of Commons Library, a UK-based government body, indicated that around 25,000 individuals in the UK suffered from inherited retinal diseases in 2024, representing an annual rise of 2%. Consequently, the growing occurrence of inherited retinal diseases is a significant impetus for the leber congenital amaurosis market.

Leber Congenital Amaurosis Market Segment Breakdown: Which Categories Lead On Revenue?

The leber congenital amaurosis market covered in this report is segmented –

1) By Treatment Type: Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices, Other Treatments

2) By Age Of Onset: Congenital Leber Congenital Amaurosis (LCA) (From Birth), Early Childhood Leber Congenital Amaurosis (LCA) (1-5 Years), Late-Onset Leber Congenital Amaurosis (LCA) (6 Years And Above)

3) By Distribution Channel: Direct Tender, Retail Sales

4) By End User: Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings, Other End Users

Subsegments:

1) By Gene Therapy: RPE65 Gene Replacement Therapy, CRISPR-Based Gene Editing, AAV (Adeno-Associated Virus) Vector Therapy, Emerging Experimental Gene Therapies

2) By Pharmaceutical Drugs: Retinoid-Based Therapies, Neuroprotective Agents, Anti-Inflammatory Drugs, Antioxidant Therapies

3) By Retinal Prosthesis: Implantable Retinal Chips, Artificial Retinal Stimulation Devices, Bionic Eye Technology

4) By Assistive Devices: Low Vision Aids, Screen Readers and Braille Devices, Mobility Aids for Vision Impairment

5) By Other Treatments: Stem Cell Therapy, Optogenetics-Based Treatments, Visual Rehabilitation Programs, Nutritional and Dietary Interventions

Leber Congenital Amaurosis Market Growth Trends Reshaping The Competitive Landscape

Leading companies in the leber congenital amaurosis market are concentrating on developing innovative solutions, such as RNA-based treatments, to enhance vision restoration and disease management. These RNA-based treatments utilize RNA molecules to address diseases by targeting genetic processes, including mRNA vaccines, siRNA therapies, antisense oligonucleotides, and RNA aptamers. For example, in January 2025, Laboratoires Théa S.A.S., a France-based pharmaceutical company, introduced Sepul Bio. This dedicated business unit aims to advance RNA therapies for inherited retinal diseases, specifically targeting sepofarsen for leber congenital amaurosis 10 (LCA10) and ultevursen for USH2A-associated retinitis pigmentosa. With the successful dosing of the first patient in the LUNA Phase 2b clinical trial for ultevursen, Sepul Bio is prepared to achieve significant advancements in managing these rare genetic disorders.

Leber Congenital Amaurosis Market Leading Players And Competitive Positioning

Major companies operating in the leber congenital amaurosis market are Sanofi S.A., Novartis AG, Astellas Pharma Inc., Invitae Corporation, Novelion Therapeutics Inc., Andelyn Biosciences Inc., CD Genomics Inc., Editas Medicine Inc., MeiraGTx Holdings plc, Sangamo Therapeutics Inc., LKC Technologies Inc., Aldeyra Therapeutics Inc., Asper Biogene OÜ, Allergan Inc., ProQR Therapeutics N.V., GenSight Biologics S.A., Ocugen Inc., Ophthotech Corporation, Atsena Therapeutics Inc., HuidaGene Therapeutics Co. Ltd.

View The Full Leber Congenital Amaurosis Market Report:

https://thebusinessresearchcompany.com/report/leber-congenital-amaurosis-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Leber Congenital Amaurosis Market Regional Split: Which Areas Are Fueling Growth?

North America was the largest region in the leber congenital amaurosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leber congenital amaurosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model